MSA-C (multiple system atrophy, cerebellar type) is a rare, progressive neurodegenerative disease that primarily damages the cerebellum and brainstem, the parts of the brain responsible for coordination, balance, and movement. It belongs to a group of conditions called synucleinopathies, where a protein called alpha-synuclein builds up abnormally in the brain. Median survival from symptom onset is roughly 8 to 9 years, though individual experiences vary widely.
What Happens in the Brain
In a healthy brain, alpha-synuclein is a small protein that sits at nerve terminals and helps shuttle chemical signals between cells. In MSA-C, this protein clumps together inside support cells called oligodendroglia, forming deposits known as glial cytoplasmic inclusions. These deposits are the defining feature of the disease under a microscope.
The damage starts in a very specific location. The earliest buildup of abnormal protein appears in the white matter just beneath the cerebellum and in the nerve fibers that connect the brainstem to the cerebellum. As the disease progresses, Purkinje cells (the large neurons in the cerebellum that fine-tune movement) begin to die off, and the loss worsens over time. Eventually, the abnormal protein spreads to other brain regions including the basal ganglia, spinal cord, and even parts of the cortex, which explains why symptoms broaden as the disease advances.
Core Symptoms
Because the cerebellum is hit first, the earliest and most prominent symptoms involve coordination. Most people notice problems with walking: an unsteady, wide-based gait that can look similar to walking on a rocking boat. Limb coordination deteriorates too, making tasks like reaching for a glass or buttoning a shirt increasingly difficult. Speech often becomes slurred and uneven, a pattern called ataxic dysarthria. Eye movements may also become jerky or imprecise.
What separates MSA-C from other causes of ataxia is autonomic failure, meaning the body’s automatic systems start breaking down alongside the movement problems. The most common autonomic issue is orthostatic hypotension: blood pressure drops sharply when you stand up, causing lightheadedness, blurred vision, or fainting. This is defined as a fall of at least 20 points in systolic blood pressure (the top number) or 10 points in diastolic pressure within three minutes of standing. Research shows that MSA-C patients are disproportionately represented among those with severe orthostatic hypotension. Bladder dysfunction, including urinary urgency and incontinence, is also very common and often appears early in the disease course.
How MSA-C Differs From MSA-P
Multiple system atrophy comes in two main subtypes, classified by whichever motor problem dominates. MSA-C is the cerebellar type, where balance and coordination problems lead the picture. MSA-P is the parkinsonian type, where stiffness, slowness, and tremor resemble Parkinson’s disease. Both subtypes share the same underlying protein pathology and similar autonomic dysfunction. The distinction is clinical, based on which symptoms are most prominent.
The relative frequency of each subtype depends on geography. In European and North American populations, MSA-P tends to be more common. In Asian populations, MSA-C predominates, sometimes accounting for roughly two-thirds of all MSA cases. This pattern suggests genetic or environmental factors influence which brain regions are most vulnerable. Globally, MSA as a whole is rare, with prevalence estimates ranging from about 0.5 to 17 per 100,000 people depending on the country and study methods.
How It’s Diagnosed
There is no single blood test or scan that confirms MSA-C. Diagnosis relies on a combination of clinical features and imaging. The current diagnostic framework, established by an international consensus group, uses three levels of certainty: possible, probable, and definite (definite can only be confirmed after death, with brain tissue analysis).
For a probable diagnosis, a person must have a progressive condition that began in adulthood, with clear cerebellar ataxia plus well-documented autonomic failure, such as orthostatic hypotension or significant bladder problems. The condition also must not respond well to levodopa, the standard Parkinson’s medication, which helps distinguish MSA from Parkinson’s disease. For a possible diagnosis, the criteria are slightly less strict but still require at least one sign of autonomic dysfunction alongside cerebellar symptoms, plus one additional clinical or imaging finding.
MRI plays an important supporting role. In MSA-C, brain scans typically show shrinkage of the cerebellum, the pons (a key brainstem structure), and the middle cerebellar peduncles, which are the thick fiber bundles connecting the two. A characteristic pattern on certain MRI sequences, sometimes called the “hot cross bun sign,” shows a cross-shaped bright signal within the shrunken pons. When this sign appears alongside clinical cerebellar ataxia, it strongly supports the diagnosis.
Treatment and Daily Management
No treatment currently slows or stops MSA-C. Management focuses entirely on relieving symptoms and maintaining function for as long as possible.
For the ataxia itself, medication options are limited. Riluzole, a drug originally developed for ALS, showed modest improvement in a small clinical trial, with patients gaining better gait stability, reduced tremor, and clearer speech over eight weeks. However, the study was small, included a mix of ataxia types, and the observation period was short, so the benefit for MSA-C specifically remains uncertain. Potential side effects include liver enzyme elevation and dizziness.
Physical therapy is one of the more consistently helpful strategies. Intensive rehabilitation programs, combining physical and occupational therapy for several hours daily over a period of weeks, have shown improvements in ataxia symptoms and the ability to perform everyday tasks. Speech therapy can help with the dysarthria that makes communication progressively harder. The goal of all these therapies is to maintain independence and safety for as long as the disease allows.
Managing autonomic symptoms is equally important and often has a bigger impact on day-to-day quality of life than treating the ataxia. For orthostatic hypotension, practical measures like standing up slowly, wearing compression garments, increasing salt and fluid intake, and sleeping with the head of the bed slightly elevated can reduce fainting episodes. Blood pressure can also swing high when lying down (supine hypertension), which complicates management since treatments that raise standing blood pressure can worsen the problem at night.
Prognosis and Disease Progression
MSA-C is relentlessly progressive. Median survival from symptom onset is approximately 8 years for the cerebellar subtype, roughly similar to the 9-year median seen in MSA-P. Some people live significantly longer, while others decline more quickly. The pace of progression varies, but most people eventually need a wheelchair within a few years of diagnosis and become increasingly dependent for daily care.
The spread of alpha-synuclein pathology through the brain follows a somewhat predictable pattern: starting in the cerebellum and brainstem, then moving into the basal ganglia and spinal cord, and eventually reaching the hippocampus, amygdala, and cortex. This progression explains why late-stage MSA-C can involve symptoms well beyond coordination problems, including cognitive changes, swallowing difficulties, and breathing irregularities during sleep. Respiratory complications, particularly stridor (a high-pitched breathing sound caused by vocal cord dysfunction) and aspiration pneumonia, are among the most common causes of death.